HHC
LGND icon

Hutchin Hill Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Hutchin Hill Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,282
Closed -$1.47M – 953
2017
Q1 		$1.47M Buy
+22,282
New +$1.47M 0.04% 391

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Hutchin Hill Capital's LGND Position: Q2 2017 in Review

Hutchin Hill Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2017, closing a stake of 22,282 shares — an estimated $1.47M sold.

Hutchin Hill Capital first reported a position in LGND in Q1 2017 and held it in 1 quarter. The position peaked at $1.47M in Q1 2017. 266 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

  • Hutchin Hill Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 22,282 Ligand Pharmaceuticals shares in Q2 2017, an estimated $1.47M.
  • Hutchin Hill Capital first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Hutchin Hill Capital's Ligand Pharmaceuticals position peaked at $1.47M in Q1 2017.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.